ArticleMolecules (Basel, Switzerland)2015
Novel orally active analgesic and anti-inflammatory cyclohexyl-N-acylhydrazone derivatives.
Article in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 46 citations in OpenAlex.
- Design, Synthesis, and Biological Evaluation ofMicroorganisms · 2025Article
- Colorimetric and Fluorometric N-Acylhydrazone-based Chemosensors for Detection of Single to Multiple Metal Ions: Design Strategies and Analytical Applications.Journal of fluorescence · 2025Review
- Exploring the Structural Versatility and Dynamic Behavior of Acyl/Aroyl Hydrazones: A Comprehensive Review.Topics in current chemistry (Cham) · 2025Review
- Stereochemical insights into β-amino-RSC advances · 2024Article
- Review
- Anti-Inflammatory Activity ofPharmaceuticals (Basel, Switzerland) · 2023Article
- Synthesis, Biological, Spectroscopic and Computational Investigations of NovelMolecules (Basel, Switzerland) · 2023Article
- Molecular Hybridization Strategy on the Design, Synthesis, and Structural Characterization of Ferrocene-Molecules (Basel, Switzerland) · 2022Article
- Design and Synthesis In Silico Drug-like Prediction and Pharmacological Evaluation of Cyclopolymethylenic Homologous of LASSBio-1514.Molecules (Basel, Switzerland) · 2021Article
- Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (MRSC medicinal chemistry · 2021Article
- Natural product inspired optimization of a selective TRPV6 calcium channel inhibitor.RSC medicinal chemistry · 2020Article
- Synthesis and pharmacological evaluation of novel isoquinoline N-sulphonylhydrazones designed as ROCK inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2018Article
- Synthesis, Structure, Chemical Stability, and In Vitro Cytotoxic Properties of Novel Quinoline-3-Carbaldehyde Hydrazones Bearing a 1,2,4-Triazole or Benzotriazole Moiety.Molecules (Basel, Switzerland) · 2018Article
- Synthesis, solubility, plasma stability, and pharmacological evaluation of novel sulfonylhydrazones designed as anti-diabetic agents.Drug design, development and therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The N-acylhydrazone (NAH) moiety is considered a privileged structure, being present in many compounds with diverse pharmacological activities. Among the activities attributed to NAH derivatives anti-inflammatory and analgesic ones are recurrent. As part of a research program aiming at the design of new analgesic and anti-inflammatory lead-candidates, a series of cyclohexyl-N-acylhydrazones 10-26 were structurally designed from molecular modification on the prototype LASSBio-294, representing a new class of cycloalkyl analogues. Compounds 10-26 and their conformationally restricted analogue 9 were synthetized and evaluated as analgesic and anti-inflammatory agents in classical pharmacologic protocols. The cyclohexyl-N-acylhydrazones 10-26 and the cyclohexenyl analogue 9 showed great anti-inflammatory and/or analgesic activities, but compound 13 stood out as a new prototype to treat acute and chronic painful states due to its important analgesic activity in a neuropathic pain model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.